Amylyx Pharmaceuticals

Amylyx Pharmaceuticals is a company deeply committed to addressing the significant unmet needs of communities facing neurodegenerative and endocrine diseases. Our customers, individuals living with conditions like amyotrophic lateral sclerosis (ALS), Wolfram syndrome, post-bariatric hypoglycemia (PBH), and progressive supranuclear palsy (PSP), confront daily challenges and a future often marked by relentless disease progression and limited, if any, treatment options. This is why we pursue our mission with a profound sense of urgency, rigorous scientific investigation, and an unwavering dedication to these patient communities. We understand that for those affected by these devastating illnesses, and for their families and caregivers, time is of the essence.

Our approach is rooted in connection – a connection between our dedicated team and the people we aim to serve, a connection between complex scientific questions and innovative solutions, and a connection between insightful discoveries and decisive actions. Founded in 2013 by Joshua Cohen and Justin Klee, Amylyx was born from a desire to understand the fundamental mechanisms of neuronal cell death and to translate that understanding into meaningful therapies. We are currently advancing a pipeline of investigational therapies, including AMX0035 and avexitide, where we believe they can make the greatest impact. This involves matching these potential treatments to diseases based on well-defined mechanistic rationale, clear clinical outcomes, and robust preclinical data. Even when faced with setbacks, such as the recent voluntary withdrawal of RELYVRIO/ALBRIOZA for ALS following a Phase 3 trial that did not meet its primary endpoint, our commitment to patients and scientific integrity remains steadfast. We continue to explore AMX0035 for other conditions like Wolfram syndrome and progressive supranuclear palsy, and are advancing avexitide for post-bariatric hypoglycemia, always striving to bring new hope and improved moments to those who need them most.